consumer genomics
SNP chip data often reported by consumer genomics companies should not be considered for clinical decisions without additional validation, warn researchers.
The consumer genomics company's existing offering, called AncestryHealth, sold clinician-ordered tests that were not cleared or approved by the FDA.
While the company's new 510(k) cuts down some of the burden, consumers are still advised to consult their healthcare provider before making any changes to their treatments.
The company said the product will give customers information about their genetic risk for certain diseases.
The companies will join forces and create a new app called My Next Health, which helps gauge risk for certain conditions, including the coronavirus.
Nebula is pitching this new product as a more secure and informative alternative to mainstream consumer genomic products.
The cuts equal a 14% reduction in the consumer genomic company's workforce.
The Israel-based company is offering 11 genetic risk tests, three polygenic risk tests and 15 carrier status reports.
The companies will provide certain consumers an easy-to-understand report describing their recent tests, and may receive another at little to no cost if recommended by a genetic counselor.
Reactions to the news are mixed, with some experts saying the test is unlikely to make much of a difference.